Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Income from Continuing Operations of 505063.0 for Q1 2026, down 104.48% year-over-year from 11262161.0 in Q1 2025, and down 127.09% on a QoQ basis from 1864092.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Income from Continuing Operations data on file, last reported at 505063.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 104.48% year-over-year to 505063.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23704641.0 (down 221.89% YoY) and the FY2025 annual result came in at 6643141.0, down 254.99% from the prior year.
- Income from Continuing Operations slipped to 505063.0 in Q1 2026 per NEUP's latest filing, from 1864092.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11262161.0 in Q1 2025 and bottomed at 15157166.0 in Q2 2025.
- The 4-year median for Income from Continuing Operations is 1943349.0 (2024), against an average of 1551087.73.
- Peak annual rise in Income from Continuing Operations reached 505.38% in 2025, while the deepest fall reached 1130.95% in 2025.
- Tracing NEUP's Income from Continuing Operations over 4 years: stood at 4554424.0 in 2023, then soared by 57.33% to 1943349.0 in 2024, then jumped by 195.92% to 1864092.0 in 2025, then plunged by 127.09% to 505063.0 in 2026.
- Per Business Quant, the three latest NEUP Income from Continuing Operations figures stand at 505063.0 (Q1 2026), 1864092.0 (Q4 2025), and 9906504.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -505,063.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -505,063.00 |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -9.35 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | -804,787.00 |
| Jun 30, 2024 | -867,530.00 |
| Mar 31, 2024 | -2.78 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |